Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
If you have type 2 diabetes, the most useful news today is that common blood pressure drugs may help prevent kidney disease, GLP-1 medicines (the weight-loss and diabetes shots) look safe and helpful even for people on dialysis, and some diabetes drugs were linked to better kidney function. Most of the rest of today's sweep was brand-new drug trials that are just getting started with no results yet, along with early lab work and small look-back studies that hint at links between kidneys and things like diet, minerals, and urine tests but don't prove cause. For now, none of it changes daily care, but it's worth asking your doctor about blood pressure and diabetes medicines that protect the kidneys.
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.
This review combined the results of many studies on GLP-1 drugs in people whose kidneys have failed and who need dialysis. Pulling the studies together, it found these drugs were both safe and helpful for this group. Because it pools many studies rather than one, this is among the stronger kinds of evidence, though it depends on the quality of the studies it included.
Treatment outcomes and safety of telitacicept in reducing proteinuria and hematuria for refractory childhood IgA vasculitis nephritis
This study looked at telitacicept, a newer drug, in children with a hard-to-treat kidney inflammation caused by IgA vasculitis. It reported less protein and blood in the urine, which are signs the kidney filter is under less strain. This was a small treatment study without a comparison group, so it shows a link, not firm proof the drug caused the improvement.
Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older: A Population-Based Cohort Study
This study followed adults aged 75 and older in the community after screening them for kidney disease using KDIGO guidelines. It found that the screening results helped predict who was more likely to have poor health outcomes. Because it observed people rather than testing a treatment, it shows that screening is linked to risk, not that screening itself changes outcomes.
Asymptomatic kidney changes discovered during occupational health screening: age-dependent trends from a large cohort
In a large group of workers, routine health checks found early kidney changes that most people could not feel. These changes became more common with older age. This shows a link between age and quiet kidney damage, not proof that age causes it. It is a reminder that kidney problems can be silent and show up on simple tests.
Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease
In children with chronic kidney disease, the diabetes drug dapagliflozin was linked to better kidney function and less protein leaking into the urine. Protein in the urine is a sign of kidney stress. This shows a link, not firm proof, and most study of this drug so far was done in adults. Larger trials in children are still needed.
Prevention of new-onset chronic kidney disease with renin–angiotensin system blockers in type 2 diabetes with preserved kidney function
This study looked at people with type 2 diabetes who still had healthy kidneys. Those taking blood pressure drugs called ACE inhibitors or ARBs seemed less likely to develop new kidney disease. These drugs relax blood vessels and ease pressure inside the kidney. The finding shows a link and cannot fully prove the drugs prevent kidney disease on their own.
Clinicopathological features and outcomes of glomerular microangiopathy: a retrospective cohort study
This is a look-back study of people with damage to the tiny blood vessels inside the kidney's filters. It describes how these patients looked and how they did over time. A study like this can show a link but cannot prove what caused the outcomes. Detailed numbers were not in the summary we received.
Genetic and environmental risk factors for intracranial aneurysm and subarachnoid haemorrhage among patients with Autosomal Dominant Polycystic Kidney Disease
People with the inherited kidney disease PKD can get weak spots in brain blood vessels (aneurysms) that may burst. This study looked at which genetic and lifestyle factors raise that risk. It found links, not proof of cause. It is a preprint, not yet reviewed by other scientists.
The Urine Ammonium-pH Index is a Measure of Kidney Tubular Function
Researchers tested a urine measure, called the ammonium-pH index, to check how well the kidney's small tubes are working. Worse scores went along with faster loss of kidney function. This shows a link, not proof, and it needs more testing. It is a preprint, not yet peer reviewed.
Integrated Analysis of Zinc, Copper, and Magnesium Homeostasis in Pediatric Idiopathic Nephrotic Syndrome: A Prospective Cohort Study with Serial Clinical Evaluation
This study followed children with a kidney condition that leaks large amounts of protein into the urine (nephrotic syndrome). Researchers tracked three minerals: zinc, copper, and magnesium. It is an observational study, so it can show links but not prove cause. It suggests mineral balance is worth watching in these children.
Change of prognostic nutritional index after three months of initial hemodialysis is a predictor of long-term outcomes for patients with uremia
This study looked at dialysis patients and a score based on nutrition and immune health. A drop in the score after three months went along with worse long-term outcomes. It shows a link, not cause. It is a preprint, not yet reviewed by other scientists.
Spectrum of Anti–Factor B-Associated Glomerular Diseases in Adults
This study looked at adults who make an antibody that attacks part of the immune system called factor B. Doctors reviewed patient cases to describe which kidney diseases show up with this antibody. It shows a link between the antibody and certain kidney diseases, not proof of cause. It helps doctors recognize a rare condition.
Retinal Changes in Chronic Kidney Disease: A Spectral-Domain Optical Coherence Tomography Study Correlated with Biochemical Parameters.
This study used a detailed eye scan to look at the retina, the light-sensing layer at the back of the eye, in people with chronic kidney disease. It compared eye changes with blood test results. It shows a link between kidney disease and changes in the eye, not proof that one causes the other. The eye may offer a window into kidney health.
Urinary Dickkopf-3 reflects renal and vascular damage in diabetic kidney disease: A cross-sectional study.
This study measured a protein called Dickkopf-3 in the urine of people with diabetic kidney disease. Higher levels lined up with more damage to the kidneys and blood vessels. Because it was a snapshot in time, it shows a link, not proof of cause. The urine test may help spot who is getting worse.
Metabolomics-Defined Subtypes of Prediabetes and Risk of Cardiovascular-Kidney-Metabolic Outcomes.
This study used detailed blood chemistry to sort people with prediabetes into subtypes. It then checked which subtypes had more heart, kidney, and metabolic problems. Because it looked at existing data, it shows links, not proof of cause. It may help find who is at higher risk earlier.
The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.
This study checked whether a heart-failure risk score can predict who benefits from finerenone, a kidney and heart drug, in people who have both kidney disease and type 2 diabetes. It found a link between the score and heart-failure risk. Because this is an analysis of existing data, it shows a pattern, not proof that the score causes anything.
Association Between Dietary Magnesium Intake and All-Cause Mortality in Patients with Chronic Kidney Disease: Insights from NHANES 1999-2018.
This study used a large US health survey to see if people with chronic kidney disease who ate more magnesium lived longer. Higher magnesium in the diet was tied to a lower chance of death from any cause. Because it only looked at existing data, it shows a link, not proof that magnesium is the reason. It cannot yet tell us how much magnesium to eat.
Network pharmacology and experimental verification reveal the mechanism of hederagenin in suppressing podocyte injury in focal segmental glomerular sclerosis
Researchers tested hederagenin, a plant compound, to see if it could protect the kidney's filter cells in a scarring disease called FSGS. In lab tests it seemed to reduce damage to those cells. This was done in cells and lab models, not in people, so it is only an early signal.
A-to-I RNA editing in kidney tissue from patients with nephrotic syndrome
Researchers studied kidney tissue from people with a disease that leaks protein into the urine (nephrotic syndrome). They looked at tiny chemical edits to RNA that may fuel inflammation. This was lab work on tissue samples, not a treatment tested in people. It is an early preprint, not yet reviewed by other scientists.
Heme-induced kallikrein-kinin system activation in hemolytic uremic syndrome
In a disease called hemolytic uremic syndrome, red blood cells break apart and release a molecule called heme. This lab study looked at how heme switches on a blood-clotting and inflammation pathway that can harm the kidneys. The work was done in the lab, not tested as a treatment in people. It points to a possible target for future drugs.